Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948558 | 1.00 | KAT6A (0.32) | KAT6ANCF1 | |
| SCHEMBL14948548 | 1.00 | KAT6A (0.32) | KAT6ANCF1 | |
| SCHEMBL2048600 | 0.98 | NCF1 (0.34) | KAT6ANCF1 | |
| SCHEMBL20161410 | 0.86 | CYP1A2 (0.35) | — | |
| SCHEMBL16707752 | 0.86 | CYP1A2 (0.35) | — | |
| SCHEMBL20161474 | 0.86 | CYP1A2 (0.35) | — | |
| SCHEMBL26814535 | 0.81 | SLC6A3 (0.33) | — | |
| SCHEMBL9801833 | 0.81 | SLC6A3 (0.33) | — | |
| SCHEMBL14664303 | 0.81 | SLC6A3 (0.33) | — | |
| SCHEMBL7374703 | 0.80 | SIGMAR1 (0.32) | NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109384246-A | A kind of AEI structure molecular screen and its preparation method and application | 中触媒新材料股份有限公司 | 2019-02-26 | — | — | CN | claimed |
| WO-2023184327-A1 | KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2023107648-A2 | SYNTHESIS OF ESTER, CARBONATE, AND CARBAMATE-DERIVED NOVEL BIODEGRADABLE IONIZABLE LIPIDS FROM METHYL RICINOLEATE OR METHYL 12-HYDROXYSTEARATE AND ITS APPLICATIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-20080138427-A1 | Reduced variation in the dissolution profile of a biologically active substance; pharmaceutical, drug sprayed while spraying a binding liquid to the cores; centrifugal fluidized bed coating granulation machine set to1.5 g/cm2 | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2008-06-12 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7365077-B2 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20070270434-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1852100-A1 | METHOD FOR PRODUCING GRANULES | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070141137-A1 | Stable capsule preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070141137-A1 | Stable capsule preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | KAT6A 1759/4885NCF1 1348/4885 |
| US-20080138427-A1 | Reduced variation in the dissolution profile of a biologically active substance; pharmaceutical, drug sprayed while spraying a binding liquid to the cores; centrifugal fluidized bed coating granulation machine set to1.5 g/cm2 | SERPINA6, CMA1, CRH | KAT6A 3120/4885NCF1 2903/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | KAT6A 1854/4885NCF1 1273/4885 |
| US-20070270434-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARD, PPARG, PPARA | KAT6A 1655/4885NCF1 3316/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | KAT6A 2268/4885NCF1 1867/4885 |
| US-20070141137-A1 | Stable capsule preparation | PGA5, PPIA, RPS2 | KAT6A 2579/4885NCF1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.